Asbestos Research Today is a free monthly online journal that collates and summarizes the latest research about Asbestos, including details on mesothelioma, lung disease, dangers, effects, risks.

Volume 1 (2004), Issue 3 (November)

1. Assessment of 18F-fluorodeoxyglucose dual-head gamma camera in asbestos lung diseases.
   Eur Respir J, 24(5): 814-21. [Abstract] [Full-text]
2. Induction of stem cell factor/c-Kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells.
   J Biol Chem, 279(45): 46706-14. [Abstract] [Full-text]
3. The gamma-glutamylcysteine synthetase and glutathione regulate asbestos-induced expression of activator protein-1 family members and activity.
   Cancer Res, 64(21): 7780-6. [Abstract] [Full-text]
4. Cell type-specific effects of asbestos on intracellular ROS levels, DNA oxidation and G1 cell cycle checkpoint.
   Oncogene, 23(54): 8834-40. [Abstract] [Full-text]
5. Explaining differences in incidence rates of pleural mesothelioma between Sweden and the Netherlands.
   Int J Cancer, 113(2): 298-301. [Abstract] [Full-text]
6. Malignant pleural mesothelioma metastasis to the mandible.
   Int J Oral Maxillofac Surg, 33(8): 798-800. [Abstract] [Full-text]
7. Evaluation of the size and type of free particulates collected from unused asbestos-containing brake components as related to potential for respirability.
   Am J Ind Med, 46(6): 545-53. [Abstract] [Full-text]
8. Effects of asbestos and smoking on the levels and rates of change of lung function in a crocidolite exposed cohort in Western Australia.
   Thorax, 59(12): 1052-6. [Abstract] [Full-text]
9. Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor in mesothelioma.
   Int J Cancer, 113(3): 406-14. [Abstract] [Full-text]
10. The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma.
    Clin Cancer Res, 10(22): 7655-61. [Abstract] [Full-text]

© 2004-2008 Asbestos Research Today. All Rights Reserved.